![]() |
|
Research No link with GLP-1 drugs reducing risk of macular degeneration (diabetes fashions) - Printable Version +- Scivillage.com Casual Discussion Science Forum (https://www.scivillage.com) +-- Forum: Culture (https://www.scivillage.com/forum-49.html) +--- Forum: Style & Fashion (https://www.scivillage.com/forum-132.html) +--- Thread: Research No link with GLP-1 drugs reducing risk of macular degeneration (diabetes fashions) (/thread-20879.html) |
No link with GLP-1 drugs reducing risk of macular degeneration (diabetes fashions) - C C - Jul 18, 2026 Study finds no statistical link between use of semaglutide and other GLP-1 drugs and risk of degenerative eye disease in adults with type 2 diabetes https://www.eurekalert.org/news-releases/1136615 INTRO: An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — a type of medication that mimics the GLP-1 hormone — to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases. A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) — a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye — in adults with type 2 diabetes without a prior history of GLP-1 use. A peer-reviewed report of the work, funded by the National Institutes of Health, published online in Ophthalmology... (MORE - no ads) RE: No link with GLP-1 drugs reducing risk of macular degeneration (diabetes fashions) - Magical Realist - Jul 18, 2026 Quote:A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) — a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye — in adults with type 2 diabetes without a prior history of GLP-1 use. "Lowering your A1C does not prevent Age-Related Macular Degeneration (AMD) because they are distinct diseases. However, tight blood sugar control helps prevent diabetic retinopathy and diabetic macular edema, which can cause overlapping vision loss. A breakdown of how blood sugar and eye health are connected: Distinct Conditions: AMD is an age-related deterioration of the macula, while diabetic eye disease is caused by high blood sugar damaging retinal blood vessels. Overlapping Risks: While lowering A1C doesn't stop AMD, poorly controlled diabetes can worsen existing AMD and speed up vision loss. Diabetic Eye Disease: Managing your A1C (often recommended to stay below 7%) significantly reduces the risk of developing diabetic retinopathy and diabetic macular edema. Potential Meds: Emerging studies suggest that the diabetes medication metformin may have protective, anti-inflammatory properties that could potentially lower the odds of developing or progressing AMD." |